New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Identifying the support needed by children with sarcoma
Development of a paediatric version of the Sarcoma Assessment Measure (SAM-Paeds): a specific tool for assessing quality of life in children with sarcoma
Investigating the potential benefits of proton beam therapy for abdominal tumours
The use of proton beam therapy to improve outcomes in childhood abdominal tumours
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Preventing heart problems in childhood cancer survivors through physical activity
Promoting physical activity in childhood cancer survivors: Using qualitative and co-design methods to inform the development of an evidence-based intervention
Do national advisory panels improve outcomes for patients?
Evaluation of national advisory panels for childhood cancer
Do scans during follow-up improve survival rates?
Does routine surveillance imaging improve survival after relapsed extra-cranial solid tumours? A systematic review and meta-analysis